We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.01% | 128.25 | 655 | 10:40:02 |
From May 2019 to May 2024
By Josh Beckerman
Merck & Co.'s (MRK) cancer drug Keytruda didn't meet its co-primary endpoints in a Phase 3 trial for treatment of patients with advanced hepatocellular carcinoma.
"While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings" from a Phase 2 study, Merck said.
Results will be presented at an upcoming medical meeting and have been shared with the U.S. Food and Drug Administration.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 19, 2019 16:38 ET (21:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
